8-K
filed June 22, 2023, 7:59 PM ET
ticker ELDN
CIK 0001404281
other material
confidence high
sentiment neutral
materiality 0.35
Eledon shareholders approve 9.6M share increase to 2020 incentive plan at annual meeting
Eledon Pharmaceuticals, Inc.
- Amended 2020 Long Term Incentive Plan: share reserve raised from 4.86M to 14.46M shares.
- Two Class III directors re-elected: David-Alexandre C. Gros and Jan Hillson (each ~7.1M for votes).
- Advisory say-on-pay passed with 7.05M for vs 234K against; auditor KMJ Corbin ratified with 9.62M for.
- Plan extended through April 26, 2033; additional 9.6M shares approved by stockholders.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Eledon Pharmaceuticals, Inc. shareholders approved Election of Class III Directors at the 2023-06-21 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-21
Exact text from the filing
Proposal 1: The stockholders of the Company elected each of David-Alexandre C. Gros, M.D. and Jan Hillson, M.D. as Class III Directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2026 and until each of their successors has been duly elected and qualified, or until their earlier death, resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Eledon Pharmaceuticals, Inc. shareholders approved Approval of amendment to the 2020 Incentive Plan to increase shares available by 9,600,000 at the 2023-06-21 meeting.
- Outcome
- passed
- Meeting
- 2023-06-21
Exact text from the filing
Proposal 2: The stockholders of the Company approved an amendment to the Company's 2020 Incentive Plan, increasing the aggregate number of shares available for issuance by 9,600,000 shares.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Eledon Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-21 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-21
Exact text from the filing
Proposal 3: The stockholders of the Company approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the 2023 definitive proxy statement on Schedule 14A, as follows: For Against Abstain Broker Non-Vote 7,051,556 234,105 257,656 2,272,638
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Eledon Pharmaceuticals, Inc. shareholders approved Ratification of KMJ Corbin & Company LLP as independent registered public accounting firm at the 2023-06-21 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-21
Exact text from the filing
Proposal 4: The stockholders of the Company ratified the appointment of KMJ Corbin & Company LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. The results of the stockholders' vote with respect to the ratification were as follows: For Against Abstain 9,624,236 187,115 4,604
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.